Overall, these data have led to a therapy shift into the AML treatment scenario, establishing gilteritinib as the new gold standard for R/R FLT3-mutated AML, and incorporation of the drug into frontline regimens will likely become the standard therapeutic strategy for de novo FLT3-mutated AML. Here, FLT3 is linked to acute myeloid leukemia.